Roivant has had a big year of success on multiple fronts - CEO Matt Gline shares an update on a key launch, and two closely watched programs
He discusses the launch of brepocitinib in dermatomyositis, which is underway right now, and shares an update on mosliciguat in pulmonary hypertension and learnings from the most recent readout of IMVT-1402 (FcRn).









.png)